Exhibit 10.01

 

Collaboration Agreement between the Company
and BioPharmaWorks LLC

 

THIS COLLABORATION AGREEMENT (this “Agreement”) is made and entered into as of
September __, 2015 (the “Effective Date”), by and between Lixte Biotechnology
Holdings, Inc., a Delaware corporation (“Lixte”) and BioPharmaWorks LLC, a
Connecticut limited liability company (“BioPharma”) with reference to the
following:

 

Lixte wishes to engage BioPharma to work with Lixte in a collaborative mode to
maximize the value of Lixte’s intellectual property, and, in connection
therewith, to provide certain services, as hereinafter defined, and BioPharma
has agreed to provide the services in accordance with the terms and conditions
of this Agreement.

 

NOW THEREFORE, for good and valuable consideration, including the herein
promises, covenants, agreements, representations and warranties, the receipt and
legal sufficiency of which is hereby acknowledged, accepted and agreed to, Lixte
and BioPharma, intending to be legally bound, hereby agree as follows:

 

1. BioPharma hereby agrees to perform the services (the “Services”) as set forth
on Schedule A. This Agreement shall apply to any and all Services performed
pursuant hereto. BioPharma shall take all reasonable steps to become
knowledgeable with Lixte’s patent portfolio (currently consisting of 22 issued
or pending applications) and additional existing and to be developed preclinical
data on potential drug candidates.

 

2. Unless sooner terminated pursuant to Section 7 hereof, this Agreement shall
be deemed effective as of the Effective Date, and shall continue in full force
and effect for an initial period of two (2) years from such Date and shall
automatically renew for subsequent annual periods unless terminated by a party
pursuant to written notice delivered to the other party not less than 60 days
prior to the expiration of the applicable annual period.

 

3. In consideration of the Services to be rendered hereunder, the following
shall apply:

 

(a) Lixte hereby grants and shall promptly issue to BioPharma 1,000,000 shares
of Lixte Common Stock (the “Shares”) vesting on the Effective Date, it being
understood that BioPharma shall have the right to designate up to six employees
of BioPharma to receive up to an aggregate of 60,000 Shares subject to such
employees executing a representation letter in form and substance satisfactory
to Lixte.

 

(b) Lixte hereby grants BioPharma five-year warrants to purchase 1,000,000
Shares (the “Warrants”) in the form of Exhibit A and Exhibit B attached hereto
divided into two tranches:

 

(i) Warrants to purchase 500,000 shares at $1.00/share vesting on the first
anniversary of the Effective Date, provided the Agreement is then still in force
and effect.

 

(ii) Warrants to purchase 500,000 shares at $2.00/share vesting on the second
anniversary of the Effective Date, provided the Agreement is then still in force
and effect.

 

(c) Lixte shall pay BioPharma a monthly fee of $10,000 payable within fifteen
business days after receipt of an invoice from BioPharma, provided that Lixte
shall have the right to cancel the monthly payment plan and negotiate an hourly
rate for individual tasks mutually agreed upon by BioPharma and Lixte.

 

 Exhibit 10.01 - Page 1

 

 

4. BioPharma shall keep in strictest confidence and shall not, without the prior
written authorization of Lixte, publish, disclose, disseminate or use for any
purpose other than as contemplated by this Agreement any and all information
disclosed to or developed by BioPharma in connection with this Agreement or with
providing any Services performed hereunder (collectively the “Information”).
This obligation of non-disclosure and non-use shall not apply to Information
which: (i) is, at the time of disclosure or thereafter, becomes publicly
available through no fault of BioPharma; (ii) BioPharma can demonstrate through
competent written records was in its possession before receipt; (iii) is
disclosed to BioPharma by a third party with the legal right to do so; or (iv)
is required to be disclosed pursuant to judicial process, court order or
administrative request, provided that BioPharma shall so notify Lixte
sufficiently prior to disclosing such Information as to permit Lixte to seek a
protective order. BioPharma shall ensure that each of its employees,
subcontractors, consultants, and agents who have access to Information
understand the confidential nature thereof and agree to be bound by the
obligations set forth in this Section 4. BioPharma shall not have any
publication rights and all of the same shall belong to Lixte.

 

5. All information, data, reports, writings, ideas, inventions and other work
product, in any form whatsoever, both tangible and intangible, developed as a
result of BioPharma’s performance of the Services (collectively, the “Works”),
shall be the sole and exclusive property of Lixte. BioPharma hereby assigns, and
to the extent any such assignment cannot be made at present hereby agrees to
timely assign to Lixte and further agrees to cause its employees to assign to
Lixte all rights, title and interest in and to any such Works. All such
assignments now and in the future shall be immediately made when requested by
Lixte and shall be made without any additional consideration or fee. During the
term of this Agreement or at any time after the termination thereof, at the
request of Lixte, BioPharma shall make, or cause its employees to make promptly,
or cooperate in the making thereof, an application for United States letters
patent and foreign letters patent or for copyright registration on any materials
BioPharma may develop in the course of performing the Services and developing
the Works contemplated by this Agreement. Furthermore, BioPharma shall assign,
or shall cause its employees and all others involved with or who participated in
providing the Services, to assign, to Lixte or its designee: (i) any such
application for copyright registration or for letters patent and patents issuing
thereon; (ii) any other rights arising out of the Works; and (iii) any other
intellectual property rights arising out of or related to this Agreement.

 

For avoidance of doubt, BioPharma agrees that any theory, discovery, invention,
formulation, know-how, method, technology, development, confidential
information, enhancement, modification, improvement or trade secret owned by or
licensed to Lixte as of the Effective Date or at any time during the Term of
this Agreement, shall remain exclusively owned or licensed by Lixte (the “Lixte
Background Intellectual Property”). In addition, any and all discoveries,
inventions or improvements thereto, together with any enhancements, additions,
trade secrets or know-how created, developed, conceived or reduced to practice
by BioPharma (whether patentable or not), during the term of this Agreement and
in the performance, directly or indirectly, of the Services (the “Services IP”)
shall be solely owned by Lixte, and BioPharma shall execute or cause the
execution of any agreement reasonably requested by Lixte to evidence the
foregoing, including, without limitation, obtaining from BioPharma’s employees
or consultants appropriate assignments of Services IP.

 

6. BioPharma shall be identified on Lixte’s web site and as appropriate in
Lixte’s press releases (subject to the reasonable approval by BioPharma) as a
participant and collaborator of Lixte in Lixte’s drug discovery, development and
commercialization.

 

7. This Agreement may be terminated by a party in the event that: (i) the other
party becomes insolvent or is unable to pay its debts as they become due, or a
petition in bankruptcy or for reorganization is filed by or against it, or a
receiver is appointed of the whole or any substantial portion of its property;
or (ii) the other party is in material breach of its obligations hereunder,
which breach remains uncured for ten (10) business days following receipt of
written notice from the other specifying the breach, then the other party shall
have the right to immediately terminate this Agreement, without prejudice to its
other rights or remedies, by written notice of such election.

 

 Exhibit 10.01 - Page 2

 

 

8. BioPharma shall perform the Services: (i) in a first class professional
manner in accordance with the terms and conditions of this Agreement, (ii) in
conformance with that level of care and skill ordinarily exercised in similar
circumstances by providers of the same or similar services and (iii) in
compliance with all applicable federal, state and local laws, rules,
regulations, orders, ordinances and binding obligations. BioPharma warrants that
BioPharma is presently, and will remain, for the term of this Agreement and any
extension thereof, free from any commitments or conflicts of interest that would
impair BioPharma from rendering its undivided loyalty to Lixte or providing the
Services in an accurate and timely manner as directed by Lixte and shall devote
such time and effort as reasonably required to provide the Services hereunder.
BioPharma shall require any subcontractors or consultants retained to assist
BioPharma in the performance of this Agreement to agree to maintain itself free
from conflicts of interest pursuant to terms substantially similar to those set
forth in this Section 8.

 

9. BioPharma shall not subcontract this Agreement or any portion thereof,
without the prior written approval of Lixte. Any such approval shall not relieve
BioPharma of its obligations under this Agreement. Further, BioPharma may not
assign, delegate or transfer any of its rights or obligations under this
Agreement without the written consent of Lixte. Any attempted assignment,
delegation or transfer in breach of this Section 9 shall be null and void.

 

10. Any Services performed by BioPharma for Lixte under this Agreement are to be
performed by BioPharma in BioPharma’s capacity as an independent contractor.
Neither BioPharma nor its employees, agents or representatives are employees of
Lixte, and BioPharma shall have no right to enter into any agreement which binds
or otherwise commits Lixte to any obligation. BioPharma retains the sole right
to hire, discipline, evaluate and terminate its own employees and to set their
hours, wages and terms and conditions of employment in accordance with law and
BioPharma’s obligations herein. All income, employment and other similar taxes
required to be withheld and/or paid with respect to all services provided
hereunder will be timely paid by BioPharma directly to the appropriate
governmental agency. The employees, representatives or agents of BioPharma are
not entitled to and will not receive from Lixte in connection with the Services,
any benefits normally provided by Lixte to its employees. BioPharma agrees to
defend, indemnify and hold Lixte harmless against any claim that Lixte is
jointly or severally liable or obligated to BioPharma’s employees, agents,
employees’ representative, a benefit plan or any governmental fund or entity on
the basis of a statute, regulation or common law duty relating to employment.

 

11. Except as set forth in Schedule A or as otherwise approved by Lixte,
BioPharma shall be responsible for all expenses and costs in providing the
Services hereunder.

 

12. All notices required or permitted hereunder shall be given in writing and
sent by facsimile transmission, or mailed postage prepaid by certified or
registered mail, or sent by a nationally recognized express courier service, or
hand delivered at the following addresses:

 

  To Lixte:

Lixte Biotechnology Holdings, Inc.

248 Route 25A, No. 2

East Setauket, New York 11733

Attention: President

Email: JKovach@Lixte.com

        With a copy to:

TroyGould PC

1801 Century Park East, Suite 1600

Los Angeles, California 90067

Attention: David L. Ficksman, Esq.

Email: DFicksman@TroyGould.com

        To BioPharma:

BioPharmaWorks LLC

1084 Shennecossett Road

Groton, Connecticut 06340

Attention: Robert Volkmann

Email: ravolkmann@gmail.com

 

Any notice, if mailed properly addressed, postage prepaid, shall be deemed made
three (3) days after the date of mailing as indicated on the certified or
registered mail receipt, or on the next business day if sent by express courier
service or on the date of delivery or transmission if hand delivered or sent by
electronic transmission.

 

 Exhibit 10.01 - Page 3

 

 

13. BioPharma hereby confirms, that the Shares, the Warrants and any shares of
Common Stock issuable upon exercise of the Warrants (the “Warrant Shares”) to be
issued by BioPharma hereunder will be acquired for investment for BioPharma’s
own account, not as a nominee or agent, and not with a view to the resale or
distribution of any part thereof, and that BioPharma has no present intention of
selling, granting any participation in, or otherwise distributing the same.
BioPharma further represents that BioPharma does not presently have any
contract, undertaking, agreement or arrangement with any person to sell,
transfer or grant participations to such person or to any third person, with
respect to any of the Shares, the Warrants or the Warrant Shares (collectively,
the “Securities”). BioPharma understands that the Securities have not been, and
will not be, registered under the Securities Act of 1933, as amended (the
“Securities Act”), by reason of a specific exemption from the registration
provisions of the Securities Act which depends upon, among other things, the
bona fide nature of the investment intent and the accuracy of BioPharma’s
representations as expressed herein. BioPharma understands that the Securities
are “restricted securities” under applicable U.S. federal and state securities
laws and that, pursuant to these laws, BioPharma must hold the Securities
indefinitely unless they are registered with the Securities and Exchange
Commission and qualified by state authorities, or an exemption from such
registration and qualification requirements is available. BioPharma acknowledges
that Lixte has no obligation to register or qualify the Securities for resale.
BioPharma further acknowledges that if an exemption from registration or
qualification is available, it may be conditioned on various requirements
including, but not limited to, the time and manner of sale, the holding period
for the Securities, and on requirements relating to Lixte which are outside of
BioPharma’s control, and which Lixte is under no obligation and may not be able
to satisfy. BioPharma understands that the Securities may bear a restricted
legend . BioPharma is an accredited investor as defined in Rule 501(a) of
Regulation D promulgated under the Securities Act.

 

14. No Shares, including any Shares issued to employees of BioPharma pursuant to
Section 3(a) or transferred pursuant to the provisions of this Section 14 and
the Warrant Shares, may be sold, exchanged, assigned, pledged or otherwise
disposed of for a period of two years from the Effective Date except in
connection with estate planning purposes. Notwithstanding the foregoing or the
provisions of Section 13, a portion of the Securities may be transferred by
BioPharma to its employees, consultants or members subject to any such
transferee executing a representation letter in form and substance satisfactory
to Lixte.

 

15. Any controversy or dispute arising during under this Agreement, which is not
settled between the parties within 30 days, shall be settled by binding
arbitration in New York, New York, according to the commercial arbitration rules
of the American Arbitration Association. This Agreement shall be governed by and
construed in accordance with the internal laws of the State of New York without
regard to principles of conflicts of law. In the event of litigation relating to
the subject matter of this Agreement (whether in contract, tort, or otherwise),
the non-prevailing party shall reimburse the prevailing party for all reasonable
attorney fees and costs resulting therefrom.

 

16. This Agreement represents the entire understanding of the parties with
respect to the subject matter hereof and merge and supersedes all prior and
contemporaneous agreements or understandings, oral or written, with respect
thereto. This Agreement shall not be modified except by a written agreement
signed by the parties hereto specifying that it is a modification to the
Agreement. The failure of a party to insist upon strict adherence to any term of
this Agreement on any occasion shall not be considered a waiver or deprive that
party of the right to insist upon strict adherence to that term or any other
term of this Agreement. Any waiver must be in writing and signed by the party
making the waiver. The invalidity or unenforceability of any term or provision
of this Agreement shall not affect the validity or enforceability of any other
term or provision hereof.

 

17. The provisions of Sections 4, 5, 7, 10, 13, 14 and 15 shall survive the
expiration or termination of this Agreement.

 

[Remainder of Page Intentionally Left Blank]

 

 Exhibit 10.01 - Page 4

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed
by their respective duly authorized representatives as of the day and year first
above written, This Agreement may be executed in multiple counterparts which
shall be deemed to be an original and collectively shall constitute one
Agreement.

 

  Lixte Biotechnology Holdings, Inc.         By:       John Kovach, M.D.    
President and Chief Executive Officer         BioPharmaWorks LLC         By:    
Name: Robert Volkmann   Title: Manager

 

 Exhibit 10.01 - Page 5

 

 

SCHEDULE A

 

(1) Assist Lixte with prioritization of steps to commercialize its products.    
(2) Advise Lixte as to steps to strengthen its present and future patent
portfolio.     (3) Be available for consultation in drug discovery and
development ranging from chemical and biochemical characterization to patent
review as needed by Lixte     (4) Identify providers and oversee the quality and
accomplishment of specific tasks needed for meeting the requirements of the FDA
and the pharmaceutical industry for clinical use and commercialization of new
compounds. BioPharma will manage specific projects such as the synthesis and
evaluation of new compounds by outside experts. The costs of specific physical
tasks-drug synthesis and biochemical and biological characterization are the
responsibility of Lixte.     (5) Assist Lixte in identifying and gaining entrée
to large pharmaceutical companies with potential interest in Lixte products.    
(6) Assist Lixte in preparing and, as appropriate, delivering presentations
concerning Lixte’s products to regulatory agencies, pharmaceutical companies,
and other interested parties including potential investors.     (7) Assist in
advising the Board of Directors of Lixte with respect to Lixte’s scientific
program for a period of up to 3 months in the event that the CEO and scientific
leader of Lixte is unable to carry out this duty.     (8) Provide a monthly
report to Lixte of its activities under this Agreement.

 

 Schedule A to Collaboration Agreement
Page 1

 

 

EXHIBIT A

 

THE WARRANT EVIDENCED OR CONSTITUTED HEREBY, AND ALL SHARES OF COMMON STOCK
ISSUABLE HEREUNDER, HAVE BEEN AND WILL BE ISSUED WITHOUT REGISTRATION UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND MAY NOT BE SOLD,
OFFERED FOR SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED WITHOUT REGISTRATION
UNDER THE ACT UNLESS EITHER (i) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL,
IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY, TO THE EFFECT THAT
REGISTRATION IS NOT REQUIRED IN CONNECTION WITH SUCH DISPOSITION OR (ii) THE
SALE OF SUCH SECURITIES IS MADE PURSUANT TO SEC RULE 144.

 

WARRANT TO PURCHASE COMMON STOCK

 

OF

 

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

 

September 14, 2015

 

THIS CERTIFIES THAT, for value received BioPharmaWorks LLC (“Holder”) is
entitled, subject to the terms and conditions of this Warrant, at any time or
from time to time after the first anniversary of the issuance date of this
Warrant (the “Effective Date”), and before 5:00 p.m., Eastern Time, on the fifth
(5th) anniversary of the date hereof (the “Expiration Date”), to purchase from
the Company, 500,000 shares of Common Stock of Lixte Biotechnology Holdings,
Inc. (the “Company”) at a price per share equal to $1.00 (the “Purchase Price”).
Both the number of shares of Common Stock purchasable upon exercise of this
Warrant and the Purchase Price are subject to adjustment and change as provided
herein.

 

1. CERTAIN DEFINITIONS. As used in this Warrant the following terms shall have
the following respective meanings:

 

1.1 “Fair Market Value” of a share of Common Stock as of a particular date shall
mean:

 

(a) If traded on a securities exchange or the Nasdaq National Market, the Fair
Market Value shall be deemed to be the average of the closing prices of the
Common Stock of the Company on such exchange or market over the five (5) trading
days ending immediately prior to the applicable date of valuation;

 

(b) If actively traded over-the-counter, the Fair Market Value shall be deemed
to be the average of the closing bid prices over the thirty (30)-day period
ending immediately prior to the applicable date of valuation; and

 

(c) If there is no active public market, the Fair Market Value shall be the
value thereof, as agreed upon by the Company and the Holder; provided, however,
that if the Company and the Holder cannot agree on such value, such value shall
be determined by an independent valuation firm experienced in valuing businesses
such as the Company and jointly selected in good faith by the Company and the
Holder. Fees and expenses of the valuation firm shall be paid for by the
Company.

 

1.2 “Registered Holder” shall mean any Holder in whose name this Warrant is
registered upon the books and records maintained by the Company.

 

Exhibit A to
Collaboration Agreement
Page 1

 

 

1.3 “Warrant” as used herein, shall include this Warrant and any warrant
delivered in substitution or exchange therefor as provided herein.

 

1.4 “Common Stock” shall mean the Common Stock of the Company and any other
securities at any time receivable or issuable upon exercise of this Warrant.

 

2. EXERCISE OF WARRANT.

 

2.1 Payment. Subject to compliance with the terms and conditions of this Warrant
and applicable securities laws, this Warrant may be exercised, in whole or in
part at any time or from time to time, on or before the Expiration Date by (a)
the delivery (including, without limitation, delivery by facsimile) of the form
of Notice of Exercise attached hereto as Exhibit A (the “Notice of Exercise”),
duly executed by the Holder, at the principal office of the Company, and (b) as
soon as practicable after such date, surrendering

 

(a) this Warrant at the principal office of the Company, and

 

(b) payment, in cash (by check) or by wire transfer, of an amount equal to the
product obtained by multiplying the number of shares of Common Stock being
purchased upon such exercise by the then effective Purchase Price (the “Exercise
Amount”).

 

2.2 Net Issue Exercise. In lieu of the payment methods set forth in Section
2.1(b) above, the Holder may elect to exchange all or some of this Warrant for
shares of Common Stock equal to the value of the amount of the Warrant being
exchanged on the date of exchange. If Holder elects to exchange this Warrant as
provided in this Section 2.2, Holder shall tender to the Company the Warrant for
the amount being exchanged, along with written notice of Holder’s election to
exchange some or all of the Warrant, and the Company shall issue to Holder the
number of shares of the Common Stock computed using the following formula:

 

  X = Y (A-B)       A  

   

Where:   X = the number of shares of Common Stock to be issued to Holder.      
  Y = the number of shares of Common Stock purchasable under the amount of the
Warrant being exchanged (as adjusted to the date of such calculation).         A
= the Fair Market Value of one share of the Common Stock.         B = Purchase
Price (as adjusted to the date of such calculation).

 

2.3 “Easy Sale” Exercise. In lieu of the payment methods set forth in Section
2.1(b) above, when permitted by law and applicable regulations (including Nasdaq
and NASD rules), the Holder may pay the Purchase Price through a “same day sale”
commitment from the Holder (and if applicable a broker-dealer (a “Dealer”)),
whereby the Holder irrevocably elects to exercise this Warrant and to sell a
portion of the shares so purchased to pay the Purchase Price and the Holder (or,
if applicable, a Dealer) commits upon sale (or, in the case of a Dealer, upon
receipt) of such shares to forward the Purchase Price directly to the Company.

 

2.4 Stock Certificates; Fractional Shares. As soon as practicable on or after
the date of any exercise of this Warrant, the Company shall issue and deliver to
the person or persons entitled to receive the same a certificate or certificates
for the number of whole shares of Common Stock issuable upon such exercise. No
fractional shares or scrip representing fractional shares shall be issued upon
an exercise of this Warrant.

 

Exhibit A to
Collaboration Agreement
Page 2

 

 

2.5 Partial Exercise; Effective Date of Exercise. In case of any partial
exercise of this Warrant, the Company shall cancel this Warrant upon surrender
hereof and shall execute and deliver a new Warrant of like tenor and date for
the balance of the shares of Common Stock purchasable hereunder. This Warrant
shall be deemed to have been exercised immediately prior to the close of
business on the date of its surrender for exercise as provided above. The person
entitled to receive the shares of Common Stock issuable upon exercise of this
Warrant shall be treated for all purposes as the holder of record of such shares
as of the close of business on the date the Holder is deemed to have exercised
this Warrant.

 

2.6 Vesting. This Warrant shall vest fully upon the first anniversary of the
date of issuance.

 

3. VALID ISSUANCE: TAXES. All shares of Common Stock issued upon the exercise of
this Warrant shall be validly issued, fully paid and nonassessable, and the
Company shall pay all taxes and other governmental charges that may be imposed
in respect of the issue or delivery thereof. The Company shall not be required
to pay any tax or other charge imposed in connection with any transfer involved
in the issuance of any certificate for shares of Common Stock in any name other
than that of the Registered Holder of this Warrant, and in such case the Company
shall not be required to issue or deliver any stock certificate or security
until such tax or other charge has been paid, or it has been established to the
Company’s reasonable satisfaction that no tax or other charge is due.

 

4. ADJUSTMENT OF PURCHASE PRICE AND NUMBER OF SHARES. The number of shares of
Common Stock issuable upon exercise of this Warrant (or any shares of stock or
other securities or property receivable or issuable upon exercise of this
Warrant) and the Purchase Price are subject to adjustment upon occurrence of the
following events:

 

4.1 Adjustment for Stock Splits, Stock Subdivisions or Combinations of Shares.
The Purchase Price of this Warrant shall be proportionally decreased and the
number of shares of Common Stock issuable upon exercise of this Warrant (or any
shares of stock or other securities at the time issuable upon exercise of this
Warrant) shall be proportionally increased to reflect any stock split or
subdivision of the Company’s Common Stock. The Purchase Price of this Warrant
shall be proportionally increased and the number of shares of Common Stock
issuable upon exercise of this Warrant (or any shares of stock or other
securities at the time issuable upon exercise of this Warrant) shall be
proportionally decreased to reflect any combination of the Company’s Common
Stock.

 

4.2 Adjustment for Dividends or Distributions of Stock or Other Securities or
Property. In case the Company shall make or issue, or shall fix a record date
for the determination of eligible holders entitled to receive, a dividend or
other distribution with respect to the Common Stock (or any shares of stock or
other securities at the time issuable upon exercise of the Warrant) payable in
(a) securities of the Company or (b) assets (excluding cash dividends paid or
payable solely out of retained earnings), then, in each such case, the Holder of
this Warrant on exercise hereof at any time after the consummation, effective
date or record date of such dividend or other distribution, shall receive, in
addition to the shares of Common Stock (or such other stock or securities)
issuable on such exercise prior to such date, and without the payment of
additional consideration therefor, the securities or such other assets of the
Company to which such Holder would have been entitled upon such date if such
Holder had exercised this Warrant on the date hereof and had thereafter, during
the period from the date hereof to and including the date of such exercise,
retained such shares and all such additional securities or other assets
distributed with respect to such shares as aforesaid during such period giving
effect to all adjustments called for by this Section 4.

 

Exhibit A to
Collaboration Agreement
Page 3

 

 

4.3 Reclassification. If the Company, by reclassification of securities or
otherwise, shall change any of the securities as to which purchase rights under
this Warrant exist into the same or a different number of securities of any
other class or classes, this Warrant shall thereafter represent the right to
acquire such number and kind of securities as would have been issuable as the
result of such change with respect to the securities that were subject to the
purchase rights under this Warrant immediately prior to such reclassification or
other change, and the Purchase Price therefor shall be appropriately adjusted,
all subject to further adjustment as provided in this Section 4. No adjustment
shall be made pursuant to this Section 4.3 upon any conversion or redemption of
the Common Stock, which is the subject of Section 4.5.

 

4.4 Adjustment for Capital Reorganization, Merger or Consolidation. In case of
any capital reorganization of the capital stock of the Company (other than a
combination, reclassification, exchange or subdivision of shares otherwise
provided for herein), or any merger or consolidation of the Company with or into
another corporation, or the sale of all or substantially all the assets of the
Company then, and in each such case, as a part of such reorganization, merger,
consolidation, sale or transfer, lawful provision shall be made so that the
Holder of this Warrant shall thereafter be entitled to receive upon exercise of
this Warrant, during the period specified herein and upon payment of the
Purchase Price then in effect, the number of shares of stock or other securities
or property of the successor corporation resulting from such reorganization,
merger, consolidation, sale or transfer that a holder of the shares deliverable
upon exercise of this Warrant would have been entitled to receive in such
reorganization, consolidation, merger, sale or transfer if this Warrant had been
exercised immediately before such reorganization, merger, consolidation, sale or
transfer, all subject to further adjustment as provided in this Section 4. The
foregoing provisions of this Section 4.4 shall similarly apply to successive
reorganizations, consolidations, mergers, sales and transfers and to the stock
or securities of any other corporation that are at the time receivable upon the
exercise of this Warrant. If the per-share consideration payable to the Holder
hereof for shares in connection with any such transaction is in a form other
than cash or marketable securities, then the value of such consideration shall
be determined in good faith by the Company’s Board of Directors. In all events,
appropriate adjustment (as determined in good faith by the Company’s Board of
Directors) shall be made in the application of the provisions of this Warrant
with respect to the rights and interests of the Holder after the transaction, to
the end that the provisions of this Warrant shall be applicable after that
event, as near as reasonably may be, in relation to any shares or other property
deliverable after that event upon exercise of this Warrant.

 

4.5 Conversion of Common Stock. In case all or any portion of the authorized and
outstanding shares of Common Stock of the Company are redeemed or converted or
reclassified into other securities or property pursuant to the Company’s
Certificate of Incorporation or otherwise, or the Common Stock otherwise ceases
to exist, then, in such case, the Holder of this Warrant, upon exercise hereof
at any time after the date on which the Common Stock is so redeemed or
converted, reclassified or ceases to exist (the “Termination Date”), shall
receive, in lieu of the number of shares of Common Stock that would have been
issuable upon such exercise immediately prior to the Termination Date, the
securities or property that would have been received if this Warrant had been
exercised in full and the Common Stock received thereupon had been
simultaneously converted immediately prior to the Termination Date, all subject
to further adjustment as provided in this Warrant. Additionally, the Purchase
Price shall be immediately adjusted to equal the quotient obtained by dividing
(x) the aggregate Purchase Price of the maximum number of shares of Common Stock
for which this Warrant was exercisable immediately prior to the Termination Date
by (y) the number of shares of Common Stock of the Company for which this
Warrant is exercisable immediately after the Termination Date, all subject to
further adjustment as provided herein.

 

Exhibit A to
Collaboration Agreement
Page 4

 

 

5. CERTIFICATE AS TO ADJUSTMENTS. In each case of any adjustment in the Purchase
Price, or number or type of shares issuable upon exercise of this Warrant, the
Chief Financial Officer or Controller of the Company shall compute such
adjustment in accordance with the terms of this Warrant and prepare a
certificate setting forth such adjustment and showing in detail the facts upon
which such adjustment is based, including a statement of the adjusted Purchase
Price. The Company shall promptly send (by facsimile and by either first class
mail, postage prepaid or overnight delivery) a copy of each such certificate to
the Holder.

 

6. LOSS OR MUTILATION. Upon receipt of evidence reasonably satisfactory to the
Company of the ownership of and the loss, theft, destruction or mutilation of
this Warrant, and of indemnity reasonably satisfactory to it, and (in the case
of mutilation) upon surrender and cancellation of this Warrant, the Company will
execute and deliver in lieu thereof a new Warrant of like tenor as the lost,
stolen, destroyed or mutilated Warrant.

 

7. RESERVATION OF COMMON STOCK. The Company hereby covenants that at all times
there shall be reserved for issuance and delivery upon exercise of this Warrant
such number of shares of Common Stock or other shares of capital stock of the
Company as are from time to time issuable upon exercise of this Warrant and,
from time to time, will take all steps necessary to amend its Certificate of
Incorporation to provide sufficient reserves of shares of Common Stock issuable
upon exercise of this Warrant. All such shares shall be duly authorized, and
when issued upon such exercise, shall be validly issued, fully paid and
non-assessable, free and clear of all liens, security interests, charges and
other encumbrances or restrictions on sale and free and clear of all preemptive
rights, except encumbrances or restrictions arising under federal or state
securities laws. Issuance of this Warrant shall constitute full authority to the
Company’s Officers who are charged with the duty of executing stock certificates
to execute and issue the necessary certificates for shares of Common Stock upon
the exercise of this Warrant.

 

8. TRANSFER AND EXCHANGE. Subject to the terms and conditions of this Warrant
and compliance with all applicable securities laws, this Warrant and all rights
hereunder may be transferred to any Registered Holder’s parent, subsidiary or
affiliate, in whole or in part, on the books of the Company maintained for such
purpose at the principal office of the Company referred to above, by the
Registered Holder hereof in person, or by duly authorized attorney, upon
surrender of this Warrant properly endorsed and upon payment of any necessary
transfer tax or other governmental charge imposed upon such transfer. Upon any
permitted partial transfer, the Company will issue and deliver to the Registered
Holder a new Warrant or Warrants with respect to the shares of Common Stock not
so transferred. Each taker and holder of this Warrant, by taking or holding the
same, consents and agrees that when this Warrant shall have been so endorsed,
the person in possession of this Warrant may be treated by the Company, and all
other persons dealing with this Warrant, as the absolute owner hereof for any
purpose and as the person entitled to exercise the rights represented hereby,
any notice to the contrary notwithstanding; provided, however, that until a
transfer of this Warrant is duly registered on the books of the Company, the
Company may treat the Registered Holder hereof as the owner for all purposes.
Any other transfer shall require the approval of the Company in its sole
discretion.

 

9. RESTRICTIONS ON TRANSFER. The Holder, by acceptance hereof, agrees that,
absent an effective registration statement filed with the Securities and
Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended
(the “Securities Act”) covering the disposition or sale of this Warrant or the
Common Stock issued or issuable upon exercise hereof, as the case may be, and
registration or qualification under applicable state securities laws, such
Holder will not sell, transfer, pledge, or hypothecate any or all of this
Warrant or such Common Stock, as the case may be, unless either (i) the Company
has received an opinion of counsel, in form and substance reasonably
satisfactory to the Company, to the effect that such registration is not
required in connection with such disposition or (ii) the sale of such securities
is made pursuant to SEC Rule 144. Notwithstanding the foregoing, it is
understood that the Holder may transfer a portion of this Warrant to employees
or consultants of Holder.

 

Exhibit A to
Collaboration Agreement
Page 5

 

 

10. COMPLIANCE WITH SECURITIES LAWS. By acceptance of this Warrant, the Holder
hereby represents, warrants and covenants that any shares of stock purchased
upon exercise of this Warrant shall be acquired for investment only and not with
a view to, or for sale in connection with, any distribution thereof; that the
Holder has had such opportunity as such Holder has deemed adequate to obtain
from representatives of the Company such information as is necessary to permit
the Holder to evaluate the merits and risks of its investment in the Company;
that the Holder is able to bear the economic risk of holding such shares as may
be acquired pursuant to the exercise of this Warrant for an indefinite period;
that the Holder understands that the shares of stock acquired pursuant to the
exercise of this Warrant will not be registered under the Securities Act (unless
otherwise required pursuant to exercise by the Holder of the registration
rights, if any, granted to the Registered Holder) and will be “restricted
securities” within the meaning of Rule 144 under the Securities Act and that the
exemption from registration under Rule 144 will not be available for at least
one (1) year from the date of exercise of this Warrant, subject to any special
treatment by the SEC for exercise of this Warrant pursuant to Section 2.2, and
even then will not be available unless a public market then exists for the
stock, adequate information concerning the Company is then available to the
public, and other terms and conditions of Rule 144 are complied with; and that
all stock certificates representing shares of stock issued to the Holder upon
exercise of this Warrant or upon conversion of such shares may have affixed
thereto a legend substantially in the following form:

 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF
ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND
RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT
AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION
THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE
FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER
OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE
SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS
IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

 

11. NO RIGHTS OR LIABILITIES AS STOCKHOLDERS. This Warrant shall not entitle the
Holder to any voting rights or other rights as a stockholder of the Company. In
the absence of affirmative action by such Holder to purchase Common Stock by
exercise of this Warrant or Common Stock upon conversion thereof, no provisions
of this Warrant, and no enumeration herein of the rights or privileges of the
Holder hereof shall cause such Holder hereof to be a stockholder of the Company
for any purpose.

 

Exhibit A to
Collaboration Agreement
Page 6

 

 

12. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company hereby represents
and warrants to Holder that:

 

12.1 Due Authorization; Consents. All corporate action on the part of the
Company, its officers, directors and stockholders necessary for (a) the
authorization, execution and delivery of, and the performance of all obligations
of the Company under, this Warrant, and (b) the authorization, issuance,
reservation for issuance and delivery of all of the Common Stock issuable upon
exercise of this Warrant, has been duly taken. This Warrant constitutes a valid
and binding obligation of the Company enforceable in accordance with its terms,
subject, as to enforcement of remedies, to applicable bankruptcy, insolvency,
moratorium, reorganization and similar laws affecting creditors’ rights
generally and to general equitable principles. All consents, approvals and
authorizations of, and registrations, qualifications and filings with, any
federal or state governmental agency, authority or body, or any third party,
required in connection with the execution, delivery and performance of this
Warrant and the consummation of the transactions contemplated hereby and thereby
have been obtained.

 

12.2 Organization. The Company is a corporation duly organized, validly existing
and in good standing under the laws of the State of Delaware and has all
requisite corporate power to own, lease and operate its property and to carry on
its business as now being conducted and as currently proposed to be conducted.

 

12.3 Valid Issuance of Stock. The outstanding shares of the capital stock of the
Company are duly and validly issued, fully paid and nonassessable, and such
shares, and all outstanding options and other securities of the Company, have
been issued in full compliance with the registration and prospectus delivery
requirements of the Securities Act and the registration and qualification
requirements of all applicable state securities laws, or in compliance with
applicable exemptions therefrom, and all other provisions of applicable federal
and state securities laws, including without limitation, anti-fraud provisions.

 

12.4 Governmental Consents. All consents, approvals, orders, authorizations or
registrations, qualifications, declarations or filings with any federal or state
governmental authority on the part of the Company required in connection with
the consummation of the transactions contemplated herein shall have been
obtained prior to and be effective as of the Effective Date.

 

13. NOTICES. Except as may be otherwise provided herein, all notices, requests,
waivers and other communications made pursuant to this Agreement shall be in
writing and shall be conclusively deemed to have been duly given (a) when hand
delivered to the other party; (b) when received when sent by facsimile at the
address and number set forth below; (c) three business days after deposit in the
U.S. mail with first class or certified mail receipt requested postage prepaid
and addressed to the other party as set forth below; or (d) the next business
day after deposit with a national overnight delivery service, postage prepaid,
addressed to the parties as set forth below with next-business-day delivery
guaranteed, provided that the sending party receives a confirmation of delivery
from the delivery service provider.

 

To the Company: To the Holder:     Lixte Biotechnology Holdings, Inc. The
address on the signature page hereto 248 Route 25A, No. 2   East Setauket, New
York 11733   Attn: John S. Kovach  

 

Each person making a communication hereunder by facsimile shall promptly confirm
by telephone to the person to whom such communication was addressed each
communication made by it by facsimile pursuant hereto but the absence of such
confirmation shall not affect the validity of any such communication. A party
may change or supplement the addresses given above, or designate additional
addresses, for purposes of this Section 13 by giving the other party written
notice of the new address in the manner set forth above.

 

Exhibit A to
Collaboration Agreement
Page 7

 

 

14. HEADINGS. The headings in this Warrant are for purposes of convenience in
reference only, and shall not be deemed to constitute a part hereof.

 

15. LAW GOVERNING. This Warrant shall be construed and enforced in accordance
with, and governed by, the laws of the State of Delaware, with regard to
conflict of law principles of such state.

 

16. NO IMPAIRMENT. The Company will not, by amendment of its Certificate of
Incorporation or bylaws, or through reorganization, consolidation, merger,
dissolution, issue or sale of securities, sale of assets or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms
of this Warrant, but will at all times in good faith assist in the carrying out
of all such terms and in the taking of all such action as may be necessary or
appropriate in order to protect the rights of the Registered Holder of this
Warrant against impairment. Without limiting the generality of the foregoing,
the Company (a) will not increase the par value of any shares of stock issuable
upon the exercise of this Warrant above the amount payable therefor upon such
exercise, and (b) will take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and
nonassessable shares of Common Stock upon exercise of this Warrant.

 

17. NOTICES OF RECORD DATE. In case:

 

17.1 the Company shall take a record of the holders of its Common Stock (or
other stock or securities at the time receivable upon the exercise of this
Warrant), for the purpose of entitling them to receive any dividend or other
distribution, or any right to subscribe for or purchase any shares of stock of
any class or any other securities or to receive any other right; or

 

17.2 of any consolidation or merger of the Company with or into another
corporation, any capital reorganization of the Company, any reclassification of
the capital stock of the Company, or any conveyance of all or substantially all
of the assets of the Company to another corporation in which holders of the
Company’s stock are to receive stock, securities or property of another
corporation; or

 

17.3 of any voluntary dissolution, liquidation or winding-up of the Company; or

 

17.4 of any redemption or conversion of all outstanding Common Stock;

 

then, and in each such case, the Company will mail or cause to be mailed to the
Registered Holder of this Warrant a notice specifying, as the case may be, (i)
the date on which a record is to be taken for the purpose of such dividend,
distribution or right, or (ii) the date on which such reorganization,
reclassification, consolidation, merger, conveyance, dissolution, liquidation,
winding-up, redemption or conversion is to take place, and the time, if any is
to be fixed, as of which the holders of record of Common Stock or (such stock or
securities as at the time are receivable upon the exercise of this Warrant),
shall be entitled to exchange their shares of Common Stock (or such other stock
or securities), for securities or other property deliverable upon such
reorganization, reclassification, consolidation, merger, conveyance,
dissolution, liquidation or winding-up. The Company shall use all reasonable
efforts to ensure such notice shall be delivered at least thirty (30) days prior
to the date therein specified.

 

18. SEVERABILITY. If any term, provision, covenant or restriction of this
Warrant is held by a court of competent jurisdiction to be invalid, void or
unenforceable, the remainder of the terms, provisions, covenants and
restrictions of this Warrant shall remain in full force and effect and shall in
no way be affected, impaired or invalidated.

 

Exhibit A to
Collaboration Agreement
Page 8

 

 

19. COUNTERPARTS. For the convenience of the parties, any number of counterparts
of this Warrant may be executed by the parties hereto and each such executed
counterpart shall be, and shall be deemed to be, an original instrument.

 

20. NO INCONSISTENT AGREEMENTS. The Company will not on or after the date of
this Warrant enter into any agreement with respect to its securities which is
inconsistent with the rights granted to the Holders of this Warrant or otherwise
conflicts with the provisions hereof. The rights granted to the Holders
hereunder do not in any way conflict with and are not inconsistent with the
rights granted to holders of the Company’s securities under any other
agreements, except rights that have been waived.

 

21. SATURDAYS, SUNDAYS AND HOLIDAYS. If the Expiration Date falls on a Saturday,
Sunday or legal holiday, the Expiration Date shall automatically be extended
until 5:00 p.m. the next business day.

 

22. ENTIRE AGREEMENT. This Warrant contains the sole and entire agreement and
understanding of the parties with respect to the entire subject matter of this
Warrant, and any and all prior discussions, negotiations, commitments and
understandings, whether oral or otherwise, related to the subject matter of this
Warrant are hereby merged herein.

 

[Signatures appear on following page.]

 

Exhibit A to
Collaboration Agreement
Page 9

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Warrant as of the
Effective Date.

 

Holder:   Lixte Biotechnology Holdings, Inc.            BioPharmaWorks LLC      
          By:     By:     Robert Volkmann     John S. Kovach   Manager    
President

 

Address: 1084 Shennecossett Road   Groton, Connecticut 06340

 

SIGNATURE PAGE TO WARRANT TO PURCHASE COMMON STOCK

 

Exhibit A to
Collaboration Agreement
Page 10

 

 

Exhibit A

 

NOTICE OF EXERCISE

 

(To be executed upon exercise of Warrant)

 

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

 

The undersigned hereby irrevocably elects to exercise the right of purchase
represented by the within Warrant Certificate for, and to purchase thereunder,
the securities of the Company, as provided for therein, and (check the
applicable box):

 

[  ] tenders herewith payment of the exercise price in full in the form of cash
or a certified or official bank check in same-day funds in the amount of
$____________ for _________ such securities.     [  ] elects the [Net Issue
Exercise][Easy Sale Exercise] option pursuant to Section 2.2 or 2.3 of the
Warrant, and accordingly requests delivery of a net of ______________ of such
securities.

 

Please issue a certificate or certificates for such securities in the name of,
and pay any cash for any fractional share to (please print name, address and
social security number):

 

Name:       Address:       Signature:  

 

Note: The above signature should correspond exactly with the name on the first
page of this Warrant Certificate or with the name of the assignee appearing in
the assignment form below.

 

If said number of shares shall not be all the shares purchasable under the
within Warrant Certificate, a new Warrant Certificate is to be issued in the
name of said undersigned for the balance remaining of the shares purchasable
thereunder rounded up to the next higher whole number of shares.

 

Exhibit A to
EXHIBIT A to
Collaboration Agreement
Page 1

 

 

Exhibit B

 

ASSIGNMENT

 

(To be executed only upon assignment of Warrant Certificate)

 

For value received, hereby sells, assigns and transfers unto
____________________________ the within Warrant Certificate, together with all
right, title and interest therein, and does hereby irrevocably constitute and
appoint ____________________________ attorney, to transfer said Warrant
Certificate on the books of the within-named Company with respect to the number
of Warrants set forth below, with full power of substitution in the premises:

  

Name(s) of Assignee(s)   Address   # of Warrants                                
                 

 

And if said number of Warrants shall not be all the Warrants represented by the
Warrant Certificate, a new Warrant Certificate is to be issued in the name of
said undersigned for the balance remaining of the Warrants registered by said
Warrant Certificate.

 

Dated:       Signature:  

 

Notice: The signature to the foregoing Assignment must correspond to the name as
written upon the face of this security in every particular, without alteration
or any change whatsoever; signature(s) must be guaranteed by an eligible
guarantor institution (banks, stock brokers, savings and loan associations and
credit unions with membership in an approved signature guarantee medallion
program) pursuant to Securities and Exchange Commission Rule 17Ad-15.

 

Exhibit B to
EXHIBIT A to
Collaboration Agreement
Page 1

 

 

EXHIBIT B

 

THE WARRANT EVIDENCED OR CONSTITUTED HEREBY, AND ALL SHARES OF COMMON STOCK
ISSUABLE HEREUNDER, HAVE BEEN AND WILL BE ISSUED WITHOUT REGISTRATION UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND MAY NOT BE SOLD,
OFFERED FOR SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED WITHOUT REGISTRATION
UNDER THE ACT UNLESS EITHER (i) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL,
IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY, TO THE EFFECT THAT
REGISTRATION IS NOT REQUIRED IN CONNECTION WITH SUCH DISPOSITION OR (ii) THE
SALE OF SUCH SECURITIES IS MADE PURSUANT TO SEC RULE 144.

 

WARRANT TO PURCHASE COMMON STOCK

 

OF

 

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

September 14, 2015

 

THIS CERTIFIES THAT, for value received BioPharmaWorks LLC (“Holder”) is
entitled, subject to the terms and conditions of this Warrant, at any time or
from time to time after the second anniversary of the issuance date of this
Warrant (the “Effective Date”), and before 5:00 p.m., Eastern Time, on the fifth
(5th) anniversary of the date hereof (the “Expiration Date”), to purchase from
the Company, 500,000 shares of Common Stock of Lixte Biotechnology Holdings,
Inc. (the “Company”) at a price per share equal to $2.00 (the “Purchase Price”).
Both the number of shares of Common Stock purchasable upon exercise of this
Warrant and the Purchase Price are subject to adjustment and change as provided
herein.

 

1. CERTAIN DEFINITIONS. As used in this Warrant the following terms shall have
the following respective meanings:

 

1.1 “Fair Market Value” of a share of Common Stock as of a particular date shall
mean:

 

(a) If traded on a securities exchange or the Nasdaq National Market, the Fair
Market Value shall be deemed to be the average of the closing prices of the
Common Stock of the Company on such exchange or market over the five (5) trading
days ending immediately prior to the applicable date of valuation;

 

(b) If actively traded over-the-counter, the Fair Market Value shall be deemed
to be the average of the closing bid prices over the thirty (30)-day period
ending immediately prior to the applicable date of valuation; and

 

(c) If there is no active public market, the Fair Market Value shall be the
value thereof, as agreed upon by the Company and the Holder; provided, however,
that if the Company and the Holder cannot agree on such value, such value shall
be determined by an independent valuation firm experienced in valuing businesses
such as the Company and jointly selected in good faith by the Company and the
Holder. Fees and expenses of the valuation firm shall be paid for by the
Company.

 

1.2 “Registered Holder” shall mean any Holder in whose name this Warrant is
registered upon the books and records maintained by the Company.

 

Exhibit B to
Collaboration Agreement
Page 1

 

 

1.3 “Warrant” as used herein, shall include this Warrant and any warrant
delivered in substitution or exchange therefor as provided herein.

 

1.4 “Common Stock” shall mean the Common Stock of the Company and any other
securities at any time receivable or issuable upon exercise of this Warrant.

 

2. EXERCISE OF WARRANT.

 

2.1 Payment. Subject to compliance with the terms and conditions of this Warrant
and applicable securities laws, this Warrant may be exercised, in whole or in
part at any time or from time to time, on or before the Expiration Date by (a)
the delivery (including, without limitation, delivery by facsimile) of the form
of Notice of Exercise attached hereto as Exhibit A (the “Notice of Exercise”),
duly executed by the Holder, at the principal office of the Company, and (b) as
soon as practicable after such date, surrendering

 

(a) this Warrant at the principal office of the Company, and

 

(b) payment, in cash (by check) or by wire transfer, of an amount equal to the
product obtained by multiplying the number of shares of Common Stock being
purchased upon such exercise by the then effective Purchase Price (the “Exercise
Amount”).

 

2.2 Net Issue Exercise. In lieu of the payment methods set forth in Section
2.1(b) above, the Holder may elect to exchange all or some of this Warrant for
shares of Common Stock equal to the value of the amount of the Warrant being
exchanged on the date of exchange. If Holder elects to exchange this Warrant as
provided in this Section 2.2, Holder shall tender to the Company the Warrant for
the amount being exchanged, along with written notice of Holder’s election to
exchange some or all of the Warrant, and the Company shall issue to Holder the
number of shares of the Common Stock computed using the following formula:

 

  X = Y (A-B)       A  

  

Where:   X = the number of shares of Common Stock to be issued to Holder.      
  Y = the number of shares of Common Stock purchasable under the amount of the
Warrant being exchanged (as adjusted to the date of such calculation).         A
= the Fair Market Value of one share of the Common Stock.         B = Purchase
Price (as adjusted to the date of such calculation).

  

2.3 “Easy Sale” Exercise. In lieu of the payment methods set forth in Section
2.1(b) above, when permitted by law and applicable regulations (including Nasdaq
and NASD rules), the Holder may pay the Purchase Price through a “same day sale”
commitment from the Holder (and if applicable a broker-dealer (a “Dealer”)),
whereby the Holder irrevocably elects to exercise this Warrant and to sell a
portion of the shares so purchased to pay the Purchase Price and the Holder (or,
if applicable, a Dealer) commits upon sale (or, in the case of a Dealer, upon
receipt) of such shares to forward the Purchase Price directly to the Company.

 

2.4 Stock Certificates; Fractional Shares. As soon as practicable on or after
the date of any exercise of this Warrant, the Company shall issue and deliver to
the person or persons entitled to receive the same a certificate or certificates
for the number of whole shares of Common Stock issuable upon such exercise. No
fractional shares or scrip representing fractional shares shall be issued upon
an exercise of this Warrant.

 

Exhibit B to
Collaboration Agreement
Page 2

 

 

2.5 Partial Exercise; Effective Date of Exercise. In case of any partial
exercise of this Warrant, the Company shall cancel this Warrant upon surrender
hereof and shall execute and deliver a new Warrant of like tenor and date for
the balance of the shares of Common Stock purchasable hereunder. This Warrant
shall be deemed to have been exercised immediately prior to the close of
business on the date of its surrender for exercise as provided above. The person
entitled to receive the shares of Common Stock issuable upon exercise of this
Warrant shall be treated for all purposes as the holder of record of such shares
as of the close of business on the date the Holder is deemed to have exercised
this Warrant.

 

2.6 Vesting. This Warrant shall vest fully upon the second anniversary of the
date of issuance, provided the Collaboration Agreement dated as of the date
hereof between the Company and Holder is then in full force and effect.

 

3. VALID ISSUANCE: TAXES. All shares of Common Stock issued upon the exercise of
this Warrant shall be validly issued, fully paid and nonassessable, and the
Company shall pay all taxes and other governmental charges that may be imposed
in respect of the issue or delivery thereof. The Company shall not be required
to pay any tax or other charge imposed in connection with any transfer involved
in the issuance of any certificate for shares of Common Stock in any name other
than that of the Registered Holder of this Warrant, and in such case the Company
shall not be required to issue or deliver any stock certificate or security
until such tax or other charge has been paid, or it has been established to the
Company’s reasonable satisfaction that no tax or other charge is due.

 

4. ADJUSTMENT OF PURCHASE PRICE AND NUMBER OF SHARES. The number of shares of
Common Stock issuable upon exercise of this Warrant (or any shares of stock or
other securities or property receivable or issuable upon exercise of this
Warrant) and the Purchase Price are subject to adjustment upon occurrence of the
following events:

 

4.1 Adjustment for Stock Splits, Stock Subdivisions or Combinations of Shares.
The Purchase Price of this Warrant shall be proportionally decreased and the
number of shares of Common Stock issuable upon exercise of this Warrant (or any
shares of stock or other securities at the time issuable upon exercise of this
Warrant) shall be proportionally increased to reflect any stock split or
subdivision of the Company’s Common Stock. The Purchase Price of this Warrant
shall be proportionally increased and the number of shares of Common Stock
issuable upon exercise of this Warrant (or any shares of stock or other
securities at the time issuable upon exercise of this Warrant) shall be
proportionally decreased to reflect any combination of the Company’s Common
Stock.

 

4.2 Adjustment for Dividends or Distributions of Stock or Other Securities or
Property. In case the Company shall make or issue, or shall fix a record date
for the determination of eligible holders entitled to receive, a dividend or
other distribution with respect to the Common Stock (or any shares of stock or
other securities at the time issuable upon exercise of the Warrant) payable in
(a) securities of the Company or (b) assets (excluding cash dividends paid or
payable solely out of retained earnings), then, in each such case, the Holder of
this Warrant on exercise hereof at any time after the consummation, effective
date or record date of such dividend or other distribution, shall receive, in
addition to the shares of Common Stock (or such other stock or securities)
issuable on such exercise prior to such date, and without the payment of
additional consideration therefor, the securities or such other assets of the
Company to which such Holder would have been entitled upon such date if such
Holder had exercised this Warrant on the date hereof and had thereafter, during
the period from the date hereof to and including the date of such exercise,
retained such shares and all such additional securities or other assets
distributed with respect to such shares as aforesaid during such period giving
effect to all adjustments called for by this Section 4.

 

Exhibit B to
Collaboration Agreement
Page 3

 

 

4.3 Reclassification. If the Company, by reclassification of securities or
otherwise, shall change any of the securities as to which purchase rights under
this Warrant exist into the same or a different number of securities of any
other class or classes, this Warrant shall thereafter represent the right to
acquire such number and kind of securities as would have been issuable as the
result of such change with respect to the securities that were subject to the
purchase rights under this Warrant immediately prior to such reclassification or
other change, and the Purchase Price therefor shall be appropriately adjusted,
all subject to further adjustment as provided in this Section 4. No adjustment
shall be made pursuant to this Section 4.3 upon any conversion or redemption of
the Common Stock, which is the subject of Section 4.5.

 

4.4 Adjustment for Capital Reorganization, Merger or Consolidation. In case of
any capital reorganization of the capital stock of the Company (other than a
combination, reclassification, exchange or subdivision of shares otherwise
provided for herein), or any merger or consolidation of the Company with or into
another corporation, or the sale of all or substantially all the assets of the
Company then, and in each such case, as a part of such reorganization, merger,
consolidation, sale or transfer, lawful provision shall be made so that the
Holder of this Warrant shall thereafter be entitled to receive upon exercise of
this Warrant, during the period specified herein and upon payment of the
Purchase Price then in effect, the number of shares of stock or other securities
or property of the successor corporation resulting from such reorganization,
merger, consolidation, sale or transfer that a holder of the shares deliverable
upon exercise of this Warrant would have been entitled to receive in such
reorganization, consolidation, merger, sale or transfer if this Warrant had been
exercised immediately before such reorganization, merger, consolidation, sale or
transfer, all subject to further adjustment as provided in this Section 4. The
foregoing provisions of this Section 4.4 shall similarly apply to successive
reorganizations, consolidations, mergers, sales and transfers and to the stock
or securities of any other corporation that are at the time receivable upon the
exercise of this Warrant. If the per-share consideration payable to the Holder
hereof for shares in connection with any such transaction is in a form other
than cash or marketable securities, then the value of such consideration shall
be determined in good faith by the Company’s Board of Directors. In all events,
appropriate adjustment (as determined in good faith by the Company’s Board of
Directors) shall be made in the application of the provisions of this Warrant
with respect to the rights and interests of the Holder after the transaction, to
the end that the provisions of this Warrant shall be applicable after that
event, as near as reasonably may be, in relation to any shares or other property
deliverable after that event upon exercise of this Warrant.

 

4.5 Conversion of Common Stock. In case all or any portion of the authorized and
outstanding shares of Common Stock of the Company are redeemed or converted or
reclassified into other securities or property pursuant to the Company’s
Certificate of Incorporation or otherwise, or the Common Stock otherwise ceases
to exist, then, in such case, the Holder of this Warrant, upon exercise hereof
at any time after the date on which the Common Stock is so redeemed or
converted, reclassified or ceases to exist (the “Termination Date”), shall
receive, in lieu of the number of shares of Common Stock that would have been
issuable upon such exercise immediately prior to the Termination Date, the
securities or property that would have been received if this Warrant had been
exercised in full and the Common Stock received thereupon had been
simultaneously converted immediately prior to the Termination Date, all subject
to further adjustment as provided in this Warrant. Additionally, the Purchase
Price shall be immediately adjusted to equal the quotient obtained by dividing
(x) the aggregate Purchase Price of the maximum number of shares of Common Stock
for which this Warrant was exercisable immediately prior to the Termination Date
by (y) the number of shares of Common Stock of the Company for which this
Warrant is exercisable immediately after the Termination Date, all subject to
further adjustment as provided herein.

 

Exhibit B to
Collaboration Agreement
Page 4

 

 

5. CERTIFICATE AS TO ADJUSTMENTS. In each case of any adjustment in the Purchase
Price, or number or type of shares issuable upon exercise of this Warrant, the
Chief Financial Officer or Controller of the Company shall compute such
adjustment in accordance with the terms of this Warrant and prepare a
certificate setting forth such adjustment and showing in detail the facts upon
which such adjustment is based, including a statement of the adjusted Purchase
Price. The Company shall promptly send (by facsimile and by either first class
mail, postage prepaid or overnight delivery) a copy of each such certificate to
the Holder.

 

6. LOSS OR MUTILATION. Upon receipt of evidence reasonably satisfactory to the
Company of the ownership of and the loss, theft, destruction or mutilation of
this Warrant, and of indemnity reasonably satisfactory to it, and (in the case
of mutilation) upon surrender and cancellation of this Warrant, the Company will
execute and deliver in lieu thereof a new Warrant of like tenor as the lost,
stolen, destroyed or mutilated Warrant.

 

7. RESERVATION OF COMMON STOCK. The Company hereby covenants that at all times
there shall be reserved for issuance and delivery upon exercise of this Warrant
such number of shares of Common Stock or other shares of capital stock of the
Company as are from time to time issuable upon exercise of this Warrant and,
from time to time, will take all steps necessary to amend its Certificate of
Incorporation to provide sufficient reserves of shares of Common Stock issuable
upon exercise of this Warrant. All such shares shall be duly authorized, and
when issued upon such exercise, shall be validly issued, fully paid and
non-assessable, free and clear of all liens, security interests, charges and
other encumbrances or restrictions on sale and free and clear of all preemptive
rights, except encumbrances or restrictions arising under federal or state
securities laws. Issuance of this Warrant shall constitute full authority to the
Company’s Officers who are charged with the duty of executing stock certificates
to execute and issue the necessary certificates for shares of Common Stock upon
the exercise of this Warrant.

 

8. TRANSFER AND EXCHANGE. Subject to the terms and conditions of this Warrant
and compliance with all applicable securities laws, this Warrant and all rights
hereunder may be transferred to any Registered Holder’s parent, subsidiary or
affiliate, in whole or in part, on the books of the Company maintained for such
purpose at the principal office of the Company referred to above, by the
Registered Holder hereof in person, or by duly authorized attorney, upon
surrender of this Warrant properly endorsed and upon payment of any necessary
transfer tax or other governmental charge imposed upon such transfer. Upon any
permitted partial transfer, the Company will issue and deliver to the Registered
Holder a new Warrant or Warrants with respect to the shares of Common Stock not
so transferred. Each taker and holder of this Warrant, by taking or holding the
same, consents and agrees that when this Warrant shall have been so endorsed,
the person in possession of this Warrant may be treated by the Company, and all
other persons dealing with this Warrant, as the absolute owner hereof for any
purpose and as the person entitled to exercise the rights represented hereby,
any notice to the contrary notwithstanding; provided, however, that until a
transfer of this Warrant is duly registered on the books of the Company, the
Company may treat the Registered Holder hereof as the owner for all purposes.
Any other transfer shall require the approval of the Company in its sole
discretion.

 

9. RESTRICTIONS ON TRANSFER. The Holder, by acceptance hereof, agrees that,
absent an effective registration statement filed with the Securities and
Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended
(the “Securities Act”) covering the disposition or sale of this Warrant or the
Common Stock issued or issuable upon exercise hereof, as the case may be, and
registration or qualification under applicable state securities laws, such
Holder will not sell, transfer, pledge, or hypothecate any or all of this
Warrant or such Common Stock, as the case may be, unless either (i) the Company
has received an opinion of counsel, in form and substance reasonably
satisfactory to the Company, to the effect that such registration is not
required in connection with such disposition or (ii) the sale of such securities
is made pursuant to SEC Rule 144. Notwithstanding the foregoing, it is
understood that the Holder may transfer a portion of this Warrant to employees
or consultants of Holder.

 

Exhibit B to
Collaboration Agreement
Page 5

 

 

10. COMPLIANCE WITH SECURITIES LAWS. By acceptance of this Warrant, the Holder
hereby represents, warrants and covenants that any shares of stock purchased
upon exercise of this Warrant shall be acquired for investment only and not with
a view to, or for sale in connection with, any distribution thereof; that the
Holder has had such opportunity as such Holder has deemed adequate to obtain
from representatives of the Company such information as is necessary to permit
the Holder to evaluate the merits and risks of its investment in the Company;
that the Holder is able to bear the economic risk of holding such shares as may
be acquired pursuant to the exercise of this Warrant for an indefinite period;
that the Holder understands that the shares of stock acquired pursuant to the
exercise of this Warrant will not be registered under the Securities Act (unless
otherwise required pursuant to exercise by the Holder of the registration
rights, if any, granted to the Registered Holder) and will be “restricted
securities” within the meaning of Rule 144 under the Securities Act and that the
exemption from registration under Rule 144 will not be available for at least
one (1) year from the date of exercise of this Warrant, subject to any special
treatment by the SEC for exercise of this Warrant pursuant to Section 2.2, and
even then will not be available unless a public market then exists for the
stock, adequate information concerning the Company is then available to the
public, and other terms and conditions of Rule 144 are complied with; and that
all stock certificates representing shares of stock issued to the Holder upon
exercise of this Warrant or upon conversion of such shares may have affixed
thereto a legend substantially in the following form:

 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF
ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND
RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT
AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION
THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE
FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER
OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE
SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS
IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

 

11. NO RIGHTS OR LIABILITIES AS STOCKHOLDERS. This Warrant shall not entitle the
Holder to any voting rights or other rights as a stockholder of the Company. In
the absence of affirmative action by such Holder to purchase Common Stock by
exercise of this Warrant or Common Stock upon conversion thereof, no provisions
of this Warrant, and no enumeration herein of the rights or privileges of the
Holder hereof shall cause such Holder hereof to be a stockholder of the Company
for any purpose.

 

Exhibit B to
Collaboration Agreement
Page 6

 

 

12. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company hereby represents
and warrants to Holder that:

 

12.1 Due Authorization; Consents. All corporate action on the part of the
Company, its officers, directors and stockholders necessary for (a) the
authorization, execution and delivery of, and the performance of all obligations
of the Company under, this Warrant, and (b) the authorization, issuance,
reservation for issuance and delivery of all of the Common Stock issuable upon
exercise of this Warrant, has been duly taken. This Warrant constitutes a valid
and binding obligation of the Company enforceable in accordance with its terms,
subject, as to enforcement of remedies, to applicable bankruptcy, insolvency,
moratorium, reorganization and similar laws affecting creditors’ rights
generally and to general equitable principles. All consents, approvals and
authorizations of, and registrations, qualifications and filings with, any
federal or state governmental agency, authority or body, or any third party,
required in connection with the execution, delivery and performance of this
Warrant and the consummation of the transactions contemplated hereby and thereby
have been obtained.

 

12.2 Organization. The Company is a corporation duly organized, validly existing
and in good standing under the laws of the State of Delaware and has all
requisite corporate power to own, lease and operate its property and to carry on
its business as now being conducted and as currently proposed to be conducted.

 

12.3 Valid Issuance of Stock. The outstanding shares of the capital stock of the
Company are duly and validly issued, fully paid and nonassessable, and such
shares, and all outstanding options and other securities of the Company, have
been issued in full compliance with the registration and prospectus delivery
requirements of the Securities Act and the registration and qualification
requirements of all applicable state securities laws, or in compliance with
applicable exemptions therefrom, and all other provisions of applicable federal
and state securities laws, including without limitation, anti-fraud provisions.

 

12.4 Governmental Consents. All consents, approvals, orders, authorizations or
registrations, qualifications, declarations or filings with any federal or state
governmental authority on the part of the Company required in connection with
the consummation of the transactions contemplated herein shall have been
obtained prior to and be effective as of the Effective Date.

 

13. NOTICES. Except as may be otherwise provided herein, all notices, requests,
waivers and other communications made pursuant to this Agreement shall be in
writing and shall be conclusively deemed to have been duly given (a) when hand
delivered to the other party; (b) when received when sent by facsimile at the
address and number set forth below; (c) three business days after deposit in the
U.S. mail with first class or certified mail receipt requested postage prepaid
and addressed to the other party as set forth below; or (d) the next business
day after deposit with a national overnight delivery service, postage prepaid,
addressed to the parties as set forth below with next-business-day delivery
guaranteed, provided that the sending party receives a confirmation of delivery
from the delivery service provider.

 

To the Company: To the Holder:     Lixte Biotechnology Holdings, Inc. The
address on the signature page hereto 248 Route 25A, No. 2   East Setauket, New
York 11733   Attn: John S. Kovach  

 

Each person making a communication hereunder by facsimile shall promptly confirm
by telephone to the person to whom such communication was addressed each
communication made by it by facsimile pursuant hereto but the absence of such
confirmation shall not affect the validity of any such communication. A party
may change or supplement the addresses given above, or designate additional
addresses, for purposes of this Section 13 by giving the other party written
notice of the new address in the manner set forth above.

 

Exhibit B to
Collaboration Agreement
Page 7

 

 

14. HEADINGS. The headings in this Warrant are for purposes of convenience in
reference only, and shall not be deemed to constitute a part hereof.

 

15. LAW GOVERNING. This Warrant shall be construed and enforced in accordance
with, and governed by, the laws of the State of Delaware, with regard to
conflict of law principles of such state.

 

16. NO IMPAIRMENT. The Company will not, by amendment of its Certificate of
Incorporation or bylaws, or through reorganization, consolidation, merger,
dissolution, issue or sale of securities, sale of assets or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms
of this Warrant, but will at all times in good faith assist in the carrying out
of all such terms and in the taking of all such action as may be necessary or
appropriate in order to protect the rights of the Registered Holder of this
Warrant against impairment. Without limiting the generality of the foregoing,
the Company (a) will not increase the par value of any shares of stock issuable
upon the exercise of this Warrant above the amount payable therefor upon such
exercise, and (b) will take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and
nonassessable shares of Common Stock upon exercise of this Warrant.

 

17. NOTICES OF RECORD DATE. In case:

 

17.1 the Company shall take a record of the holders of its Common Stock (or
other stock or securities at the time receivable upon the exercise of this
Warrant), for the purpose of entitling them to receive any dividend or other
distribution, or any right to subscribe for or purchase any shares of stock of
any class or any other securities or to receive any other right; or

 

17.2 of any consolidation or merger of the Company with or into another
corporation, any capital reorganization of the Company, any reclassification of
the capital stock of the Company, or any conveyance of all or substantially all
of the assets of the Company to another corporation in which holders of the
Company’s stock are to receive stock, securities or property of another
corporation; or

 

17.3 of any voluntary dissolution, liquidation or winding-up of the Company; or

 

17.4 of any redemption or conversion of all outstanding Common Stock;

 

then, and in each such case, the Company will mail or cause to be mailed to the
Registered Holder of this Warrant a notice specifying, as the case may be, (i)
the date on which a record is to be taken for the purpose of such dividend,
distribution or right, or (ii) the date on which such reorganization,
reclassification, consolidation, merger, conveyance, dissolution, liquidation,
winding-up, redemption or conversion is to take place, and the time, if any is
to be fixed, as of which the holders of record of Common Stock or (such stock or
securities as at the time are receivable upon the exercise of this Warrant),
shall be entitled to exchange their shares of Common Stock (or such other stock
or securities), for securities or other property deliverable upon such
reorganization, reclassification, consolidation, merger, conveyance,
dissolution, liquidation or winding-up. The Company shall use all reasonable
efforts to ensure such notice shall be delivered at least thirty (30) days prior
to the date therein specified.

 

18. SEVERABILITY. If any term, provision, covenant or restriction of this
Warrant is held by a court of competent jurisdiction to be invalid, void or
unenforceable, the remainder of the terms, provisions, covenants and
restrictions of this Warrant shall remain in full force and effect and shall in
no way be affected, impaired or invalidated.

 

Exhibit B to
Collaboration Agreement
Page 8

 

 

19. COUNTERPARTS. For the convenience of the parties, any number of counterparts
of this Warrant may be executed by the parties hereto and each such executed
counterpart shall be, and shall be deemed to be, an original instrument.

 

20. NO INCONSISTENT AGREEMENTS. The Company will not on or after the date of
this Warrant enter into any agreement with respect to its securities which is
inconsistent with the rights granted to the Holders of this Warrant or otherwise
conflicts with the provisions hereof. The rights granted to the Holders
hereunder do not in any way conflict with and are not inconsistent with the
rights granted to holders of the Company’s securities under any other
agreements, except rights that have been waived.

 

21. SATURDAYS, SUNDAYS AND HOLIDAYS. If the Expiration Date falls on a Saturday,
Sunday or legal holiday, the Expiration Date shall automatically be extended
until 5:00 p.m. the next business day.

 

22. ENTIRE AGREEMENT. This Warrant contains the sole and entire agreement and
understanding of the parties with respect to the entire subject matter of this
Warrant, and any and all prior discussions, negotiations, commitments and
understandings, whether oral or otherwise, related to the subject matter of this
Warrant are hereby merged herein.

 

[Signatures appear on following page.]

 

Exhibit B to
Collaboration Agreement
Page 9

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Warrant as of the
Effective Date.

  

Holder:   Lixte Biotechnology Holdings, Inc.       BioPharmaWorks LLC          
By:     By:     Robert Volkmann     John S. Kovach   Manager     President

 

Address: 1084 Shennecossett Road   Groton, Connecticut 06340

 

SIGNATURE PAGE TO WARRANT TO PURCHASE COMMON STOCK

 

Exhibit B to
Collaboration Agreement
Page 10

 

 

Exhibit A

 

NOTICE OF EXERCISE

 

(To be executed upon exercise of Warrant)

 

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

 

The undersigned hereby irrevocably elects to exercise the right of purchase
represented by the within Warrant Certificate for, and to purchase thereunder,
the securities of the Company, as provided for therein, and (check the
applicable box):

 

[  ] tenders herewith payment of the exercise price in full in the form of cash
or a certified or official bank check in same-day funds in the amount of
$____________ for _________ such securities.     [  ] elects the [Net Issue
Exercise][Easy Sale Exercise] option pursuant to Section 2.2 or 2.3 of the
Warrant, and accordingly requests delivery of a net of ______________ of such
securities.

 

Please issue a certificate or certificates for such securities in the name of,
and pay any cash for any fractional share to (please print name, address and
social security number):

 

Name:       Address:       Signature:  

 

Note: The above signature should correspond exactly with the name on the first
page of this Warrant Certificate or with the name of the assignee appearing in
the assignment form below.

 

If said number of shares shall not be all the shares purchasable under the
within Warrant Certificate, a new Warrant Certificate is to be issued in the
name of said undersigned for the balance remaining of the shares purchasable
thereunder rounded up to the next higher whole number of shares.

 

Exhibit A to
EXHIBIT B to
Collaboration Agreement
Page 1

 

 

Exhibit B

 

ASSIGNMENT

 

(To be executed only upon assignment of Warrant Certificate)

 

For value received, hereby sells, assigns and transfers unto
____________________________ the within Warrant Certificate, together with all
right, title and interest therein, and does hereby irrevocably constitute and
appoint ____________________________ attorney, to transfer said Warrant
Certificate on the books of the within-named Company with respect to the number
of Warrants set forth below, with full power of substitution in the premises:

 

Name(s) of Assignee(s)   Address   # of Warrants                                
                 

  

And if said number of Warrants shall not be all the Warrants represented by the
Warrant Certificate, a new Warrant Certificate is to be issued in the name of
said undersigned for the balance remaining of the Warrants registered by said
Warrant Certificate.

 

Dated:       Signature:  

 

Notice: The signature to the foregoing Assignment must correspond to the name as
written upon the face of this security in every particular, without alteration
or any change whatsoever; signature(s) must be guaranteed by an eligible
guarantor institution (banks, stock brokers, savings and loan associations and
credit unions with membership in an approved signature guarantee medallion
program) pursuant to Securities and Exchange Commission Rule 17Ad-15.

 

Exhibit B to
EXHIBIT B to
Collaboration Agreement
Page 1